Maternal and fetal outcomes in pregnancies affected by mixed connective tissue disease

Read full text Summarise with VIRAT
Authors: Shannon Y. Zhou, Lily Holden, Melody Colon, Alexandra Cregan, Sabrina C. Burn
Cited by: 0
References: 55

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: Mixed connective tissue disease (MCTD) is an autoimmune condition with overlapping features of lupus, systemic sclerosis, and polymyositis. Maternal-fetal outcomes specific to MCTD remain poorly characterized; a scoping review was conducted. Methods: Five databases were queried. Extracted data included demographics, antibody profiles, symptoms, treatments, and maternal-fetal outcomes. Descriptive analysis was performed. Results: Of 269 articles, 33 met inclusion criteria, including 375 pregnancies. Common symptoms and disease manifestations included Raynaud's phenomenon, arthralgias, and sclerodactyly. Treatments included hydroxychloroquine, azathioprine, and corticosteroids. Maternal complications included interstitial lung disease (21.4%), gestational hypertension (HTN) (15.6%), chronic HTN (7.0%), pulmonary HTN (9.8%), eclampsia (1.4%), miscarriage (20.3%), preterm birth (19.6%), and stillbirth (8.1%). Fetal complications included chondrodysplasia punctata (18.2%), demise (6.5%), neonatal lupus erythematosus (3.3%), and congenital heart block (1.0%). Conclusion: While most MCTD pregnancies resulted in live birth, they carry elevated maternal and perinatal risks that warrant heightened surveillance and tailored management.

Fields of Study & Subjects

Pregnancy and Medication Impact Systemic Lupus Erythematosus Research Systemic Sclerosis and Related Diseases

Publication details

Journal / source
Obstetric Medicine
Pages
1753495X261427244–1753495X261427244
Publication date
1 April 2026
Language
EN